Listen
DUOTRAV (travoprost, timolol) - Glaucoma and ocular hypertension
Opinions on drugs -
Posted on
Sep 12 2025
Reason for request
Modification of the listing conditions
Summary of opinion
Favourable opinion for reimbursement in the reduction of intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta blockers or prostaglandin analogues.
No clinical added value of the new form compared to the form already available.
Clinical Benefit
| Substantial |
The clinical benefit of DUOTRAV 40 µg/ml + 5 mg/ml (travoprost, timolol) eye drops, solution, packaged in a polyethylene bottle, is substantial in the MA indication. |
Clinical Added Value
| no clinical added value |
This medicinal product is a range supplement that provides no clinical added value (CAV V) compared to the form already listed. |
Documents
English version
Contact Us
Évaluation des médicaments
